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A series of selenides bearing benzensulfonamide were investigated as inhibitors of the metalloenzyme
carbonic anhydrase (CA, EC 4.2.1.1). Potent inhibitory action, in the low nanomolar range, was detected
against isoforms hCA II and VII, which are known to be involved in neuropathic pain modulation. These
selenides showed on the other hand moderate inhibition against the cytosolic isoforms hCA I and
transmembrane hCA IX. X-ray crystallographic data of two derivatives bound to hCA II allowed us to
rationalize the excellent inhibitory data. In a mice model of neuropathic pain induced by oxaliplatin,
some of the strong CA II/VII inhibitors induced a long lasting pain relieving effect.
© 2018 Elsevier Masson SAS. All rights reserved.1. Introduction
Neuropathic pain is a major public health problem that affects
approximately 6% of the adult population worldwide [1]. This
condition manifests specific symptoms such as spontaneous
burning pain and allodynia (pain that arises due to non-noxious
stimuli) due to sensory system damage or disease [1]. Such symp-
toms have a significant impact on a patient's quality of life and
social productivity. Despite several therapeutic options, treatment
or control of neuropathic pain remains challenging because of the
heterogeneous etiology and the multifactorial mechanisms un-
derlying this disease [2]. Damages to the nervous tissue induce a
complex machinery of pathophysiologic events. A peripheral nerve
lesion may provoke aberrant regeneration of the nerve, with the
neurons becoming unusually sensitive and developing an abnormal
excitability called peripheral sensitization [3,4]. On the other hand,uran).
served.a central component of pain develops by direct or indirect alter-
ations. The spinothalamic tract neurons develop an increased
background activity, coupled to enlarged receptive fields and
increased responses to afferent impulses, including the normally
innocuous stimuli. These mechanisms together with secondary
events in the central pain processing pathways contribute to the
development and maintenance of a steady-state pain condition [5].
Recently, pioneering work from Kaila and Price's groups discovered
the connection between Carbonic Anhydrases (CAs) modulation
and neuropathic pain [6,7]. These metalloenzymes catalyzed effi-
ciently the hydration of CO2 to bicarbonate and protons. Generation
of HCO3 as a reaction product of CO2 hydration is closely connected
with the physiology/biochemistry of many neurotransmitters, such
as g-aminobutyric acid (GABA) [8]. CA inhibition with the clinically
used sulfonamide acetazolamide (AAZ) augments GABAA receptor-
mediated analgesia via a spinal mechanism of action. In vivo
pharmacologic andmodeling studies showed that a loss function of
the neuron-specific potassium-chloride (Kþ-Cl-) cotransporter
KCC2 leads to a decrease in the efficacy of GABAA-mediated spinal
inhibition [7]. In order to reduced bicarbonate-dependent depo-
larization via GABAA receptors when the function of KCC2 is
Table 1
Synthesis of selenides bearing benzenesulfonamide moiety 3a-f.







a Yields are referred to isolated products.
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the negative effects of loss of KCC2 function after nerve injury [8].
The use of CAIs in the management of neuropathic pain [9] and
cerebral ischemia [10] showed very interesting results, which
might lead to new possibilities of therapeutic applications for this
class of compounds.Scheme 1. Synthesis of selenides 7a-d from2. Results and discussion
2.1. Compounds design and synthesis
The physical damage by chemotherapeutic drugs leads to
functional impairment in neurons through oxidative stress,different diselenides or selenocyanates.
Scheme 3. Synthesis of 4-(selenocyanatomethyl)benzenesulfonamide 12.
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fact, oxidative stress is identified to be responsible for the neuronal
damage in different models of neuropathies such as diabetic neu-
ropathy, acryl amide induced neuropathy and CharcoteMarie
neuropathy [11e14]. In this particular contest, our drug design is
based on the combination of sulfonamide moiety as a typical zinc
binding group (ZBG), with the well known antioxidant propriety of
organo-selenium scaffolds [15e17]. 4,40-Dis-
elanediyldibenzenesulfonamide 1 was synthesized from sulfanil-
amide in three steps using published procedures from our group
[18,19], and 1 was then treated with NaBH4 and afterwards, it was
treated in situ with the appropriate halo-alkyl derivatives (2a-f) to
synthesize the corresponding selenides (3a-f) in good yields
(Table 1).
In order to access different selenides, we used different ap-
proaches. The synthesis of compounds 7a-b was carried out ac-
cording to Scheme 1 by using the reduction reaction of diselenides
(4a-b) and 4-(bromomethyl) benzenesulfonamide (6) to afford in
good yield selenides 7a-b.
Two different amino aromatic selenocyanates (5a-b) were used
as an efficient alternative to diselenides to obtain selenides 7c-d as
outlined in Scheme 1. The key intermediates selenocyanates were
obtained according to literature procedure [20]. Compounds 5a-b
were prepared by addition of selenium dioxide to malononitrile in
DMSO at room temperature followed by reaction with the corre-
sponding aminoaryl derivatives. The amino function of 7cwas next
converted into two different moieties: (i) ureido group (10a-c)
using the corresponding isocyanate or isothiocyanate (8a-c) in
acetonitrile at room temperature as reported previously by our
group [21]; (ii) amide group (11a-c), obtained in excellent yield by
using the appropriate acyl chloride (9a-c), in THF and triethylamine
as reported in Scheme 2.Scheme 2. Synthesis of new selenides with uFinally, the further functionalization of 4-(bromomethyl) ben-
zenesulfonamide 6 was achieved by nucleophilic displacement
reactions. The reaction of 6with potassium selenocyanate afforded
the functionalized 4-methyl benzenesulfonamide in good yields
(Scheme 3).2.2. Carbonic anhydrase inhibition
All synthesized compounds, 3a-f, 7a-d, 10a-c, 11a-c and 12,
were tested in vitro for their inhibitory properties against the
physiological relevant hCA isoforms (I, II, VII, and IX) by means of a
stopped-flow carbon dioxide hydration assay [22] after a period of
15min of incubation of the enzyme and inhibitor solutions
[23e27]. Their activities were compared to the standard carbonic
anhydrase inhibitor (CAI) acetazolamide (AAZ) (Table 2).
The following SARs for the hCA isoforms considered are
reported:
i) The ubiquitous cytosolic hCA I was weakly inhibited by all
compounds except for 3f which showed a good inhibitionreido (10a-c) and amido (11a-c) groups.
Table 2
Inhibition data of human CA isoforms I, II, VII and IX with compounds 3a-f, 7a-d,
10a-c, 11a-c, 12 and AAZ by a stopped flow CO2 hydrase assay [22].
Cmp KI (nM)b
hCA I hCA II hCA VII hCA IX
3aa 261.7 41.2 0.77 12.0
3ba 256.8 9.3 0.31 8.7
3c 73.5 4.9 7.2 46.4
3d 531.2 3.9 1.8 548.6
3ea 293.5 7.6 2.0 2.2
3fa 21.9 6.3 0.24 2.6
7a 226.1 53.0 6.6 2.7
7b 953.7 70.8 645.0 337.4
7c 464.3 1.5 17.4 286.3
7d 841.1 46.9 311.8 450.1
10a 4767 220.5 295.6 1071
10b 926.8 6.0 86.0 1137
10c 755.4 0.94 3.8 697.4
11a 93.3 0.54 0.93 709.8
11b 5995 9.4 37.4 845.0
11c 2578 364.6 462.8 1006
12 70.2 14.0 0.97 4.0
AAZ 250 12.1 2.5 25.8
a Reference [19].
b Mean from 3 different assays, by a stopped flow technique (errors were in the
range of ± 5e10% of the reported values).
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3a-e and 7a-c did not modified significantly the activity. On
the other hand, the efficacy decreased to micromolar range
for the next functionalization of compound 7c with ureido
(10a-c) and amido (11a-c) moieties, except for 11awith Ki of
93.3 nM.
ii) The in vitro kinetic data showed that ureido 10c and amido
derivatives 11a were the most potent inhibitors against the
dominant cytosolic human isoform hCA II, in sub nanomolar
range (Ki 0.94 and 0.54 nM respectively), followed by the
compounds in series 3a-f (Ki 3.9e41.2 nM). Low-medium
inhibition potencies, with Ki values spanning between
220.5 and 364.6 nM, were obtained for compounds 10a and
11c.
iii) The last cytosolic human isoform studied here, hCA VII, was
potently inhibited by many compounds investigated in the
present article, in the sub or low-medium nanomolar range,
except for derivatives 7c, 10a and 11c which were active in
the high nanomolar range (Ki 295.6e645.0 nM). Conversely,
the different moieties of derivatives 3a-f and 7a-c influenced
the activity, leading to a decrease of inhibition potency of
over ten times for compounds 7a-c. Successive functionali-
zation of compound 7c with different ureido (10a-c) and
amido (11a-c) scaffolds proved to strongly change their in-
hibition profile against hCA VII, with some derivatives acting
as highly efficient and other as much less efficient hCA VII
inhibitors.
iv) Similar to hCA I, the transmembrane tumor-associated hCA
IX, was weakly inhibited by almost all compounds investi-
gated here, which showed KIs in the high nanomolar range.
Ureido and amido substituents (10a-c and 11a-c), did not
influence the efficacy of inhibition. On the other hand, the
different moieties of selenides in the compounds series 3a-f
showed multiplicity of inhibition profiles, thus proving to be
crucial for the modulation of this isoform inhibition.2.3. Structure of hCA II/Selenides ligand complex
Recent studies reported an enhanced expression of some cyto-
solic human CA isoforms (among which hCA II) in states connectedto chronic pain, such as thrombus-induced ischemic pain [28], or
chronic musculoskeletal pain in humans [29]. Thus, we next
determined the protein X-ray crystal structure of hCA II in complex
with compounds 3e and 3f (Fig. 1), in order to obtain an insight into
ligandprotein interactions at the atomic level. Selenides bearing
sulphonamide moieties 3e-f contain a short hydrophobic tail and
they were soaked into crystals of hCA II. In the absence of an in-
hibitor the Zn(II) ion is tetrahedrally coordinated by His94, His96
and His119 (hCA II numbering system labeled in blue in Fig. 1) and a
water molecule or hydroxyl ion.
In each proteineinhibitor complex, the conserved zinc-bound
water molecule is displaced by inhibitors 3e and 3f, while addi-
tional hydrogen bond interactions with residue Thr199 further
contribute to stabilize the binding (Fig. 1). The hydrophobic tail of
the inhibitors is rather peculiarly oriented, in both cases, in both
cases, are located in the hydrophobic region of the active site in a
small pocket delimited by residues Val 121, Phe131, Val135, Leu198,
and Pro202. We observed some different interactions in hydro-
phobic region between inhibitors, where, cyclohexane tail of
compound 3f was in close proximity of Phe131, on the other hand,
butyne tail of selenide 3e showed more hydrophobic interactions
with Val 135 and Leu204 residues (Fig. 1 A).
2.4. Biological assays
All these compounds are potent inhibitors of several physio-
logically relevant CA isoforms, such as hCA I, II, VII and IX. On the
other hand, there is not a precise knowledge which CA isoforms are
involved in the neuropathic pain response. For this reason, we
focused our attention on several cytosolic and transmembrane CAs
which are present in the central/peripheral nervous system such as
CA I, II, VII (the last one was predominantly expressed in the brain
and being absent in most other tissues) and CA IX (transmembrane
isoforms). Thus, we investigated different selenides such as 3a-b
and 7a in comparison to acetazolamide (AAZ), as possible pain
relievers in a mice model of neuropathic pain induced by oxali-
platin [30,31] (Fig. 2). This platinum derivative has become a valid
option as adjuvant therapy in several types of cancer [9,31]. How-
ever, a possible side effect is a painful neuropathy correlated with
characteristic alterations of the nervous system leading to a nega-
tive influence on patients' quality of life [9,31].
Mice were repeatedly treated intraperitoneally with oxaliplatin
(2.4mg kg1) for 5 consecutive days every week for 2 weeks till to
development of a significant painful neuropathy [31]. O day 14, a
single administration of compounds 3a-b and 7a significantly
reduced the lowering of pain threshold to cold stimuli. All sele-
nides, here considered, relieved pain dose-dependently
(3e100mg kg1 p.o.). Compounds 3a-b showed a significant pain
relief to higher dose (100mg kg1 p.o.) between 15 and 45min
after treatment. More effective was 7a able to restore almost the
normal pain threshold at 30min with already 30mg kg1. In the
same model, effective of AAZ was limited to 15min, moreover, the
potency and efficacy of selenides compared to AAZ were much
higher.
3. Conclusions
We have designed, synthesized and obtained the X-ray crys-
tallographic structure of a novel series of selenides bearing ben-
zenesulfonamide moieties as inhibitors of four a-carbonic
anhydrases (CAs, EC 4.2.1.1) of pharmacologic relevance, i.e., hCA I,
II, VII and IX. These selenides showed moderate inhibition against
the cytosolic isoforms hCA I and IX, but were generally effective,
low and sub nanomolar CA II, VII inhibitors. Several cytosolic and
transmembrane CAs are present in the central/peripheral nervous
Fig. 1. Inhibitors bound in the active site of hCA II. Ligands 3e (A) (PDB: 6D1L) and 3f (B) (PDB: 6D1M) are shown in green, the zinc ion is the gray sphere with its protein ligands
(His94, 96 and 119 in blue) shown as stick model, in CPK colors. Residues involved in the binding of inhibitors are also shown and labeled in red. (For interpretation of the references
to color in this figure legend, the reader is referred to the Web version of this article.)
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pain induced by oxaliplatin a long lasting pain relieving effect.4. Experimental part
4.1. Chemistry
Anhydrous solvents and all reagents were purchased from
Sigma-Aldrich, Alfa Aesar and TCI. All reactions involving air- or
moisture-sensitive compounds were performed under a nitrogen
atmosphere using dried glassware and syringes techniques to
transfer solutions. Nuclear magnetic resonance (1H NMR, 13C NMR,
19F NMR, 77Se-NMR, DEPT-135, DEPT-90, HSQC, HMBC) spectra
were recorded using a Bruker Advance III 400MHz spectrometer in
DMSO‑d6. (PhSe)2 was used as an external reference for 77Se NMR
(d¼ 461 ppm). Chemical shifts are reported in parts per million
(ppm) and the coupling constants (J) are expressed in Hertz (Hz).
Splitting patterns are designated as follows: s, singlet; d, doublet; t,
triplet; q, quadruplet; m, multiplet; brs, broad singlet; dd, double of
doublets. The assignment of exchangeable protons (OH and NH)
was confirmed by the addition of D2O. Analytical thin-layer chro-
matography (TLC) was carried out on Merck silica gel F-254 plates.
Flash chromatography purifications were performed on Merck
Silica gel 60 (230e400 mesh ASTM) as the stationary phase and
ethyl acetate/n-hexane were used as eluents. Melting points (mp)
were measured in open capillary tubes with a Gallenkamp
MPD350.BM3.5 apparatus and are uncorrected.
The solvents used in MS measures were acetone, acetonitrile
(Chromasolv grade), purchased from Sigma-Aldrich (Milan - Italy),
and mQ water 18MU, obtained from Millipore's Simplicity system
(Milan-Italy). Themass spectrawere obtained using a Varian 1200 L
triple quadrupole system (Palo Alto, CA, USA) equipped by Elec-
trospray Source (ESI) operating in both positive and negative ions.
Stock solutions of analytes were prepared in acetone at 1.0mgmL1
and stored at 4 C. Working solutions of each analyte were freshly
prepared by diluting stock solutions in a mixture of mQ H2O/ACN 1/
1 (v/v) up to a concentration of 1.0 mgmL1 Themass spectra of eachanalyte were acquired by introducing, via syringe pump at
10 mLmin1, of the its working solution. Raw-data were collected
and processed by Varian Workstation Vers. 6.8 software.
4.1.1. General procedure for the synthesis of compound 3a-f
NaBH4 (23mg, 0.60mmol, 3.0 eq.) was portionwise added to a
solution of 4,40-diselanediyldibenzenesulfonamide 1 (94mg,
0.20mmol, 1.0 eq.) in EtOH (2mL) at 0 C under inert atmosphere
(N2). After 30min, the halo-alkyl 2a-f (0.36mmol, 2.1 eq.) was
slowly added and the reaction mixture was stirred at reflux for 3 h,
until complete consumption of the starting material was observed
by TLC. The reaction was quenched by addition of saturated aq.
NH4Cl (2mL) and diluted with EtOAc (5mL). The layers were
separated and the aqueous layer was extracted with EtOAc
(2 5mL), dried over Na2SO4, filtered and concentrated under
vacuum. The crude material was purified by flash chromatography
to yield selenides (3a-f) bearing benzenesulfonamide moiety.
4.1.2. 4-((cyclopropylmethyl)selanyl)benzenesulfonamide 3cFollowing the general procedure, 4,40-dis-
elanediyldibenzenesulfonamide 1 (100mg, 0.21mmol) and (bro-
momethyl)cyclopropane 2c (60mg, 0.44mmol) gave after flash
chromatography (hexane/EtOAc 1:1) 3c (91mg, 71%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 7.72 (2H, d, J¼ 8.61 Hz), 7.67 (2H, d,
J¼ 8.58 Hz), 7.37 (2H, bs, NH2, exchange with D2O), 3.08 (2H, d,
J¼ 7.25 Hz), 1.14e1.07 (1H, m), 0.61e0.60 (2H, m), 0.31e0.29 (2H,
m). 13C NMR (100MHz, DMSO‑d6) d (ppm): 142.6, 137.5, 131.3, 127.1,
32.9,12.0, 7.7. 77Se NMR (76MHz, DMSO‑d6) d (ppm): 303.6.MS (ESI
negative) m/z: 290.1 [M-H]-,
Fig. 2. Effect of acute administration of carbonic anhydrase inhibitors 3a-b, 7a and AAZ on oxaliplatin induced neuropathic pain in the mouse Cold plate test. Oxaliplatin
(2.4mg kg1) was i.p. administered for 5 consecutive days every week for 2 weeks. Experiments were performed on day 14. **P < 0.01 vs vehicle þ vehicle treated animals; P^ < 0.05
and ^^ P < 0.01 vs oxaliplatin þ vehicle treated animals. Each value represents the mean ± S.E.M. of 10 mice performed in 2 different experimental sets.
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Following the general procedure, 4,40-dis-
elanediyldibenzenesulfonamide 1 (100mg, 0.21mmol) and benzyl
bromide 2d (75mg, 0.44mmol) gave after flash chromatography
(hexane/EtOAc 1:1) 3d (110mg, 77%). 1H NMR (400MHz, DMSO-
d6) d (ppm): 7.70 (4H, apq), 7.40e7.39 (4H, m), 7.34e7.30 (2H, m),
7.26e7.23 (1H, m), 4.39 (2H, s). 13C NMR (100MHz, DMSO‑d6)
d (ppm): 143.0, 139.0, 137.1, 131.6, 129.8, 129.3, 127.9, 127.0, 30.8.
77Se NMR (76MHz, DMSO‑d6) d (ppm): 367,7.MS (ESI negative) m/
z: 326.1 [M-H]-.
4.1.4. General procedure for the synthesis of selenides 7a-b
NaBH4 (0.60mmol, 3.0 eq.) was portionwise added to a solution
of diselenides 4a-b (0.20mmol, 1.0 eq.) in EtOH (5mL) at room
temperature under inert atmosphere (N2). After 30min, sulpho-
namide 6 (0.40mmol, 2.0 eq.) was slowly added and the reaction
mixture was stirred at room temperature for 3 h, until completeconsumption of the starting material was observed by TLC. The
reaction was quenched by addition of saturated aq. NH4Cl (4mL)
and diluted with EtOAc (5mL). The layers were separated and the
aqueous layer was extracted with EtOAc (2 5mL), dried over
Na2SO4, filtered and concentrated under vacuum. The crude ma-
terial was purified by flash chromatography (hexane/EtOAc 1:1) to
yield selenides 7a-b.
4.1.5. 4-((naphthalen-2-ylselanyl)methyl)benzenesulfonamide 7b
Following the general procedure, 1,2-di(naphthalen-2-yl)dis-
elenide 4b (83mg, 0.20mmol) and 4-(bromomethyl) benzene-
sulfonamide 6 (100mg, 0.40mmol) gave after flash
chromatography (hexane/EtOAc 1:1) 7b (215mg, 70%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 8.07 (1H, s), 7.89e7.84 (3H, m), 7.72
(2H, d, J¼ 8.41 Hz), 7.66e7.64 (2H, m), 7.56e7.51 (3H,m), 7.31 (2H,
bs, NH2, exchange with D2O), 4.45 (2H, s). 13C NMR (100MHz,
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129.3, 128.6, 128.4, 128.0, 127.6, 127.0, 126.6, 30.5. 77Se NMR
(76MHz, DMSO‑d6) d (ppm): 375.9. MS (ESI negative) m/z: 376.1
[M-H]-.
4.1.6. General procedure for the synthesis of selenides 7c-d
NaBH4 (0.80mmol, 4.0 eq.) was portionwise added to a solution
of arylselenocyanates 5a-b (0.20mmol, 1.0 eq.) in EtOH (5mL) at
room temperature under inert atmosphere (N2). After 1 h, sul-
phonamide 6 (0.20mmol, 1.0 eq.) was slowly added and the reac-
tion mixture was stirred at room temperature for 3 h, until
complete consumption of the starting material was observed by
TLC. The reaction was quenched by addition of saturated aq. NH4Cl
(4mL) and diluted with EtOAc (5mL). The layers were separated
and the aqueous layer was extracted with EtOAc (2 5mL), dried
over Na2SO4, filtered and concentrated under vacuum. The crude
material was purified by flash chromatography (hexane/EtOAc 1:1)
to yield selenides 7c-d.
4.1.7. 4-(((4-aminophenyl)selanyl)methyl)benzenesulfonamide 7cFollowing the general procedure, 4-selenocyanatoaniline 5a
(40mg, 0.20mmol) and 4-(bromomethyl) benzenesulfonamide 6
(50mg, 0.20mmol) gave after flash chromatography (hexane/
EtOAc 1:1) 7c (58mg, 85%). 1H NMR (400MHz, DMSO- d6) d (ppm):
7.70 (2H, d, J¼ 8.36 Hz), 7.36e7.29 (4H, m), 7.12 (2H, d, J¼ 8.51 Hz),
6.50 (2H, d, J¼ 8.53 Hz), 5,32 (2H, bs, NH2, exchangewith D2O), 4.05
(2H, s). 13C NMR (100MHz, DMSO‑d6) d (ppm): 149.8, 145.0, 143.0,
136.9, 129.8, 126.4, 115.5, 113.3, 32.5. 77Se NMR (76MHz, DMSO‑d6)
d (ppm): 370.7. MS (ESI negative) m/z: 341.2 [M-H]-.
4.1.8. 4-(((4-(dimethylamino)phenyl)selanyl)methyl)
benzenesulfonamide 7dFollowing the general procedure, N,N-dimethyl-4-
selenocyanatoaniline 5b (45mg, 0.20mmol) and 4-(bromo-
methyl) benzenesulfonamide 6 (50mg, 0.20mmol) gave after flash
chromatography (hexane/EtOAc 1:1) 7c (66mg, 90%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 7.70 (2H, d, J¼ 8.29 Hz), 7.36e7.28
(6H, m), 6.66 (2H, d, J¼ 8.83 Hz), 4.10 (2H, s), 2.93 (6H, s). 13C NMR
(100MHz, DMSO‑d6) d (ppm): 151.0,144.9,143.0,136.5,129.9,126.5,
114.2, 113.8, 40.8, 32.4. 77Se NMR (76MHz, DMSO‑d6) d (ppm):
365.4. MS (ESI positive) m/z: 371.2 [MþH]þ.
4.1.9. General procedure for the synthesis of selenides 10a-c
Compound 7c (0.20mmol) was dissolved in acetonitrile (5mL)
and then treated with a stoichiometric amount of isocyanates 8a-b
or isothiocyanate 8c. The mixture was stirred at room temperature
until completion (TLC monitoring). The heavy precipitate formed
was filtered off, washed with diethyl ether (10mL), and dried in
vacuo. The crude material was purified by flash chromatography
(hexane/Acetone 1:1) to yield selenides 10a-c.4.1.10. 4-(((4-(3-(4-fluorophenyl)ureido)phenyl)selanyl)methyl)
benzenesulfonamide 10a
Following the general procedure, 4-(((4-aminophenyl)selanyl)
methyl)benzenesulfonamide 7c (68mg, 0.20mmol) and 4-
Fluorophenyl isocyanate 8a (34mg, 0.20mmol) gave after flash
chromatography (hexane/Acetone 1:1) 10a (76mg, 80%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 10.26 (2H, bs, NH2, exchange with
D2O), 7.70 (2H, d, J¼ 8.37 Hz), 7.55 (2H, d, J¼ 8.67Hz), 7.44e7.37
(6H, m), 7.32 (2H, bs, NH2, exchange with D2O), 7.19 (2H, t,
J¼ 8.93 Hz) 4.25 (2H, s). 13C NMR (100MHz, DMSO‑d6) d (ppm):
170.0, 162.0 (d, J¼ 242.13 Hz), 144.4, 143.2, 139.5, 134.5, 132.9 (d,
J¼ 3.15 Hz), 131.9 (d, J¼ 8.03 Hz), 130.0, 126.5, 123.6, 120.7, 115.9 (d,
J¼ 21.20 Hz), 43.2. 19F-NMR (376MHz, DMSO‑d6) d (ppm): 116.5.




Following the general procedure, 4-(((4-aminophenyl)selanyl)
methyl)benzenesulfonamide 7c (68mg, 0.20mmol) and 3,5
dimethyl phenyl isocyanate 8b (29mg, 0.20mmol) gave after flash
chromatography (hexane/Acetone 1:1) 10b (81mg, 83%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 8.78 (1H, bs, NH2, exchange with
D2O), 8.59 (1H, bs, NH2, exchange with D2O), 7.72 (2H, d,
J¼ 8.28 Hz), 7.41e7.33 (8H, m), 7.10 (2H, bs, NH2, exchange with
D2O), 6.65 (1H, s) 4.23 (2H, s). 13C NMR (100MHz, DMSO‑d6)
d (ppm): 153.3, 144.5, 143.2, 140.4, 140.3, 138.6, 135.0, 129.9, 126.5,
124.5, 121.5, 119.7, 116.9, 31.6, 22.0. 77Se NMR (76MHz, DMSO‑d6)
d (ppm): 371.8. MS (ESI negative) m/z: 488.2 [M-H]-.
4.1.12. 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(4-((4-
sulfamoylbenzyl)selanyl)phenyl) thioureido) benzoic acid 10c
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selanyl)methyl)benzenesulfonamide 7c (68mg, 0.20mmol) and
Fluorescein isothiocyanate 8c (78mg, 0.20mmol) gave after flash
chromatography (hexane/Acetone 1:1) 10c (80mg, 55%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 10.34 (1H, bs, exchange with D2O),
10.22e10.17 (3H, m, exchange with D2O), 8.24 (1H, d, J¼ 1.49 Hz),
7.85 (2H, d, J¼ 8.20 Hz), 7.74 (2H, d, J¼ 8.25 Hz), 7.49e7.47 (5H, m),
7.34(3H, d, J¼ 4.63 Hz), 6.72 (2H, J¼ 1.93 Hz), 6.66e6.60 (4H, m),
4.33 (2H, s). 13C NMR (100MHz, DMSO‑d6) d (ppm): 180.5, 169.4,
160.5, 152.9, 144.3, 143.9, 143.8, 143.4, 139.4, 133.6, 130.1, 130.0,
129.9, 126.8, 126.7, 125.2, 118.6, 113.6, 110.7, 103.3, 84.0, 31.1. 77Se
NMR (76MHz, DMSO‑d6) d (ppm): 370.1. MS (ESI negative) m/z:
730.3 [M-H]-.
4.1.13. General procedure for the synthesis of selenides 11a-c
Compound 7c (0.2mmol) was dissolved in anhydrous THF
(5mL),then added trimethylamine (0.24mmol, 1.2 eq.) and a stoi-
chiometric amount of acyl chloride 9a-c. The mixture was stirred at
room temperature until completion (TLC monitoring). The reaction
was quenched by addition of saturated aq. NH4Cl (2mL) and diluted
with EtOAc (5mL). The layers were separated and the aqueous layer
was extracted with EtOAc (2 5mL), dried over Na2SO4, filtered
and concentrated under vacuum. The crude material was purified




Following the general procedure, 4-(((4-aminophenyl)selanyl)
methyl)benzenesulfonamide 7c (68mg, 0.20mmol) and O-Ace-
tylsalicyloyl chloride 9a (40mg, 0.20mmol) gave after flash chro-
matography (hexane/EtOAc 1:1) 11a (71mg, 70%). 1H NMR
(400MHz, DMSO- d6) d (ppm): 10.44 (1H, bs, NH2, exchange with
D2O), 7.85 (1H, d, J¼ 8.33 Hz), 7.74e7.64 (6H, m), 7.49e7.42 (4H, m),
7.34 (2H, d, J¼ 9.62 Hz), 7.29 (1H, dd, J¼ 8.09, 0.88 Hz), 4.29 (2H, s),
2.23 (3H, s). 13C NMR (100MHz, DMSO‑d6) d (ppm):169.8, 165.1,
148.9, 144.4, 143.7, 143.3, 139.4, 134,3 132.5, 130.4, 130.0, 126.8,
126.6, 124.3, 124.2, 121.4, 65.8, 21.6. 77Se NMR (76MHz, DMSO‑d6)
d (ppm): 372.6. MS (ESI negative) m/z: 502.2 [M-H]-.
4.1.15. 2,4-Dimethoxy-N-(4-((4-sulfamoylbenzyl)selanyl)phenyl)
benzamide 11b
Following the general procedure, 4-(((4-aminophenyl)selanyl)
methyl)benzenesulfonamide 7c (68mg, 0.20mmol) and 2,4-
Dimethoxybenzoyl chloride 9b (40mg, 0.20mmol) gave after
flash chromatography (hexane/EtOAc 1:1) 11b (66mg, 65%). 1H
NMR (400MHz, DMSO- d6) d (ppm): 10.01 (1H, bs, NH2, exchange
with D2O), 7.76 (1H, d, J¼ 8.57 Hz), 7.71 (4H, t, J¼ 8.41 Hz), 7.46 (2H,
d, J¼ 8.64 Hz), 7.43 (2H, d, J¼ 8.42 Hz), 7.33 (2H, bs, NH2, exchangewith D2O), 6.74, (1H, t, J¼ 2.10 Hz), 6.70 (1H, dd, J¼ 8.63, 2.29 Hz),
4.28 (2H, s), 3.98 (3H, s), 3.88 (3H, s). 13C NMR (100MHz, DMSO‑d6)
d (ppm):164.6, 163.9, 159.2, 144.4, 143.2, 139.4, 134.4, 132.8, 130.0,
126.6, 123.8, 121.4, 117.0, 106.7, 99.5, 57.1, 56.5, 31.3 77Se NMR
(76MHz, DMSO‑d6) d (ppm): 373.1. MS (ESI negative) m/z: 505.2
[M-H]-.
4.1.16. N-(4-((4-sulfamoylbenzyl)selanyl)phenyl)cinnamamide 11c
Following the general procedure, 4-(((4-aminophenyl)selanyl)
methyl)benzenesulfonamide 7c (68mg, 0.20mmol) and cinnamoyl
chloride 9c (40mg, 0.20mmol) gave after flash chromatography
(hexane/EtOAc 1:1) 11c (72mg, 76%). 1H NMR (400MHz, DMSO-
d6) d (ppm): 10.33 (1H, bs, NH2, exchange with D2O), 7.73 (2H, d,
J¼ 8.37 Hz), 7.69e7.64 (5H, m), 7.51e7.45 (5H, m), 7.43 (2H, d,
J¼ 8.38 Hz), 7.34 (2H, bs, NH2, exchange with D2O), 6.86 (1H, d,
J¼ 15.72 Hz), 4.28 (2H, s). 13C NMR (100MHz, DMSO‑d6)
d (ppm):164.5, 144.4, 143.2, 141.3, 139.6, 135.6, 134.5, 130.8, 130.0,
129.9, 128.7, 126.6, 123.9, 123.0, 120.8, 31.3 77Se NMR (76MHz,
DMSO‑d6) d (ppm): 373.5. MS (ESI negative) m/z: 471.2 [M-H]-.
4.1.17. General procedure for the synthesis of selenide 12
4-(bromomethyl) benzenesulfonamide 6 (125mg, 0.5mmol)
was dissolved in acetone (10mL) and then was added KSeCN
(87mg, 0.6mmol, 1.2 eq.). The mixture was stirred at reflux for 4 h,
until completion (TLC monitoring). The reaction was quenched by
addition of saturated aq. NH4Cl (2mL) and diluted with EtOAc
(5mL). The layers were separated and the aqueous layer was
extracted with EtOAc (2 5mL), dried over Na2SO4, filtered and
concentrated under vacuum. The crude material was purified by
flash chromatography (DCM/MeOH 90:10) to yield selenide 12
(70%).
1H NMR (400MHz, DMSO- d6) d (ppm): 7.85 (2H, d, J¼ 8.39 Hz),
7.58 (2H, d, J¼ 8.41 Hz), 7.40 (2H, bs, NH2, exchange with D2O), 4.40
(2H, s). 13C NMR (100MHz, DMSO‑d6) d (ppm): 144.2, 143.3, 130.2,
126.9, 105.6, 32.5 77Se NMR (76MHz, DMSO‑d6) d (ppm): 327.7.MS
(ESI negative) m/z: 274.0 [M-H]-.
4.2. Carbonic anhydrase inhibition
An Applied Photophysics stopped-flow instrument has been
used for assaying the CA catalyzed CO2 hydration activity [22].
Phenol red (at a concentration of 0.2mM) has been used as indi-
cator, working at the absorbance maximum of 557 nm, with 20
mMHepes (pH 7.5) as buffer, and 20mM Na2SO4 (for maintaining
constant the ionic strength), following the initial rates of the CA-
catalyzed CO2 hydration reaction for a period of 10e100 s. The
CO2 concentrations ranged from 1.7 to 17mM for the determination
of the kinetic parameters and inhibition constants. For each in-
hibitor at least six traces of the initial 5e10% of the reaction have
been used for determining the initial velocity. The uncatalyzed
rates were determined in the same manner and subtracted from
the total observed rates. Stock solutions of inhibitor (0.1mM) were
A. Angeli et al. / European Journal of Medicinal Chemistry 154 (2018) 210e219218prepared in distilled-deionized water and dilutions up to 0.01 nM
were done thereafter with the assay buffer. Inhibitor and enzyme
solutions were preincubated together for 15min at room temper-
ature prior to assay, in order to allow for the formation of the E-I
complex. The inhibition constants were obtained by non-linear
least-squares methods using PRISM 3 and the ChengePrusoff
equation, as reported earlier [23e27], and represent the mean
from at least three different determinations. All CA isoforms were
recombinant ones obtained in-house as reported earlier [24e26].
4.3. Protein X-ray crystallography
hCA II protein was purified as previously described [32]. The
protein was concentrated to about 7mgmL1 and set up in SD2
crystallization plates (Molecular Dimensions) with the following
ratio of protein plus reservoir: 200 nL þ 200 nL. The plate was
incubated at 8 C and the reservoir conditions consisted of
2.6e3.0 M ammonium sulfate with 0.1 M Tris buffer at pH 8.0 to pH
8.5. Compounds in DMSO were added to crystallization drops after
crystals had formed and several days before data were collected.
360 frames of one degree oscillation were obtained from the MX1
beamline of the Australian Synchrotron. The data were indexed
using XDS [33] and scaled using Aimless [34]. Molecular replace-
ment was done using Phaser [35] using 4cq0 as the initial starting
model. The model was manually rebuilt using Coot [36] and refined
using a combination of Phenix [37] and Refmac [38]. The compound
was placed in density using the program Afitt (OpenEye Scientific
Software) and further refined using Refmac. For structure 6D1L,
two data sets from two different crystals soaked with the same
compoundwere merged. For structure 6D1M, a single 360 data set
was obtained and used for the structure determination and
refinement.
4.4. Biological assays
Oxaliplatin (2.4mg kg1) was dissolved in 5% glucose solution
and i.p. administered for 5 consecutive days everyweek for 2 weeks
[39]. Starting from day 14, compounds and acetazolamide were
suspended in CMC and p.o. administered [40,41]. Pain-related
behavior (i.e. lifting and licking of the hind paw) were observed
and the time (seconds) of the first sign was recorded. **P < 0.01 vs
vehicle þ vehicle treated animals; ^P < 0.05 and ^^ P < 0.01 vs
oxaliplatin þ vehicle treated animals. Each value represents the
mean of 10 mice.
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